A recent, large, French, multicentric prospective study (SAFIR 01) evaluating the search for hot-spot mutations of AKT1 and PIK3CA, coupled to aCGH for copy number alterations, in more than 400 advanced breast cancer patients, demonstrated the feasibility of obtaining biopsy from metastatic tissue for molecular analyses [14]. The gene discussed is AKT1; the disease is breast carcinoma.